Simcyp signs new licensing deals worth over

Published: 12-Aug-2005

Simcyp, a Biofusion portfolio company spun out of the University of Sheffield, UK, has signed licensing deals for its predictive pharmacokinetic software and consultancy services totalling in excess of


Simcyp, a Biofusion portfolio company spun out of the University of Sheffield, UK, has signed licensing deals for its predictive pharmacokinetic software and consultancy services totalling in excess of £1.5m.

Simcyp develops software and databases designed to inform the processes of drug discovery and development by simulating virtual patient populations to identify individuals at extreme risk.

The company is supported and guided by a consortium of global pharmaceutical companies and the US FDA. Members of the consortium gain access to Simcyp's predictive pharmacokinetic software and consultancy services and contribute to the development of the services offered.

The new business achieved in 2005 has been driven by a number of new members, such as Takeda and Sanofi-Aventis, joining the consortium in recent months, partly in response to the launch of its new software package Simcyp v5.

Existing members include Pfizer and Astra Zeneca, the Universities of Manchester (UK) and Goteborg (Sweden) and Uppsala University (Sweden). These academic units use Simcyp software for both research and teaching.

You may also like